Actavis reported strong fourth quarter 2014 results.
Here are five things to know from the company's financial report:
1. Net revenue was $4.01 billion for the quarter, up 44 percent from $2.78 billion in the fourth quarter of 2013.
2. For the full year 2014, net revenue increased 48 percent to $12.8 billion, compared to net revenue of $8.7 billion for last year.
3. Cash flow from operations for the fourth quarter of 2014 was $812 million, and for the full year was $2.2 billion.
4. "We [will] continue to invest in expanding our brand and generic portfolios, with nine new product and line extension launches planned in 2015, and industry-leading expansion of our generic pipeline, with 44 abbreviated new drug applications submitted in 2014," said Brent Saunders, CEO and president of Actavis. "At year end, we had more than 65 first-to-file ANDAs and approximately 230 ANDAs in total pending at the FDA. Internationally, our business continues to grow and expand through new product launches, and we have more than 1,200 marketing authorization applications pending outside of North America."
5. Mr. Saunders also noted that the Allergen acquisition will be completed in the first or second quarter of 2015.
More articles on GI/endoscopy:
13 statistics on gastroenterologists & marijuana beliefs, use
5 recent must-reads on IBD
19 gastroenterologists with MBAs